# Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes

> **NCT06490913** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 33 (estimated)

## Conditions studied

- Liver Metastases of Colorectal Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** oxaliplatin
- **DRUG:** Cetuximab
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT06490913
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2024-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06490913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06490913, "Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06490913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*